BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 16, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Verismo licenses anti-CD19 binders to support Synkir-310 KIR-CAR T-cell therapeutic
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Verismo licenses anti-CD19 binders to support Synkir-310 KIR-CAR T-cell therapeutic
Aug. 23, 2023
No Comments
Verismo Therapeutics Inc. has entered into a licensing agreement with the University of Pennsylvania for worldwide exclusive rights for two newly discovered anti-CD19 binders, the result of a sponsored research agreement between the two parties.
BioWorld Science
CAR T
License
Cancer
Immuno-oncology